

**S s e a c R e v e s**



consensus groups, drawing on expert opinion alone, which decided on the best global policies. Over the last 15 years, however, the World Health Organization (WHO) has shown considerable leadership in malaria research, in particular ensuring the application of research synthesis to this field. It has developed partnerships between key researchers and specialists in research synthesis, particularly with The Cochrane Collaboration, to prepare and regularly update systematic reviews about the benefits and harms of new and emerging interventions to prevent and treat malaria. The WHO now formally endorses systematic reviews as integral parts of its guideline development process.<sup>2</sup>

This article highlights some of these systematic reviews and what has been learned about applying methods of research synthesis in this particular infectious disease over

Cochrane Infectious Diseases Group employed people to search specialist journals by hand to identify relevant trials.

Protocols and Reviews are prepared using standard methods and software developed by The Cochrane Collaboration.

Extensive development by The Cochrane Collaboration and its associates to improve general methods and special methods in meta-analysis (eg, for cluster randomized trials that often are used in the trials of interest to Cochrane Infectious Diseases Group authors).

Central coordination of topics for reviews to avoid duplication, and to encourage academic groups to work together rather than compete.

Inclusiveness, enabling participation of authors whatever their background or experience, with more experienced volunteers providing training and mentorship in research synthesis.

The Cochrane Infectious Diseases Group always has focused on diseases of importance in low-income tropical countries and not all infectious diseases. Part of its mission has been to help develop expertise in systematic reviews in these countries. The group's editorial team is a mixture of grant- and university-supported staff and a volunteer editorial board (see 2), which has involved technical staff from the WHO from the outset. There is now a group of over 200 authors (see 2) who are committed to preparing and updating systematic reviews in relevant areas of parasitic and infectious diseases in the tropics. To date, the authors have prepared 35 reviews in malaria, 16 in tuberculosis, 13 in diarrhea, and 25 in other neglected tropical diseases and health problems relevant to middle- and low-income countries. The only reason this endeavor is possible is through the substantial amount of time that editors and authors donate as volunteers. On top of this, some support staff and funds for larger reviews come through the Department for International Development, which is part of the UK government, for the benefit of people living in developing countries, and commissioned projects through the WHO, in particular the WHO's Special Programme for Research & Training in Tropical Diseases (TDR).

Overall, there has been a shift toward using these systematic reviews in policy. The Technical Expert Group for the World Health Organization Malaria Treatment Guidelines drew on research evidence in systematic reviews in the first edition in 2006,<sup>6</sup> categorizing decisions and recommendations using the standard approach (highest based on systematic reviews, and lowest based on expert opinion). In 2008, the WHO had decided that all guideline development needed to follow an explicit, transparent process where systematic reviews were used,<sup>2</sup> and then the evidence formally assessed using one particular system called GRADE, which stands for Grading of Recommendations Assessment, Development, and Evaluation.<sup>7</sup> These GRADE profiles then are considered by the consensus panel in forming recommendations and provide a measure of the strength of evidence behind a recommendation, and will appear in the next edition of the Global Malaria Treatment Guidelines.<sup>6,8</sup>

The article now turn to topics in malaria prevention and treatment, and the systematic reviews conducted through the Cochrane Infectious Diseases Group to discuss how they came about, and what has been learned from them.

## PREVENTING MALARIA

**D P M I I P : A P S**

The most vulnerable members of the population in malarial areas are infants, children, and pregnant women. For reasons that are partially understood, women—especially low-parity women—lose some of their acquired immunity to malaria

**B 2**  
 T e C c a e C ab a : a g ba ga a <sup>29</sup>

T C c a C ab a ca a ca c a ba ,  
 a c c a ca , b Co-  
*chrane Database of Systematic Reviews, The Cochrane Library.*

T C c a C ab a a ba ca a a c . l  
 a a a , a acc c c . T a ab  
 11,500 a 90 c . T C c a C ab a a 10 c :

1. C ab a
2. B a a
3. A ca
4. M ba
5. K a
6. S a c
7. P acc
8. E a
9. C
10. E ab ca ca

P c c a 52 C c a R G . M  
 a a b , a C c a C c a ac

*Cochrane Infectious Diseases Group*

Sc

T c c a ca c cab a . T c a ,  
 b c , a a a c c - c a - c  
 c . T a c a a a , ac a a , b c , c ,  
 cab a a c , a a , bac a , a a c a a  
 a b c ca a b ca

E a a

T a ba ca L Sc T ca M c , U K .  
 T , ba a , W a a  
 a c a c . T G W b :// .c .c c a .

when pregnant. In the early 1990s, spreading resistance to 4-aminoquinolines (eg, chloroquine and amodiaquine) meant the options for prophylaxis were limited, and this reopened the debate: if prophylaxis or intermittent preventive treatment or malaria prevention is worth doing, then one really needs to know if it is of benefit to women and their infants. Although some authors had noted a positive influence of prophylaxis on birth weight, there was a debate as to whether this might do more harm than good.<sup>9</sup>

The first systematic review on the topic was published in the *Bulletin of the WHO*.<sup>4</sup> At this time, the authors pointed out that, although policies encouraging prophylaxis and intermittent preventive treatment looked promising, the impact of various approaches was not evident for pregnant women of all parity groups together, and impacts on substantive outcomes, including anemia in the mother and perinatal mortality in the fetus, were not sufficient to be sure the intervention was effective. In









Policy makers in the WHO wanted a systematic review to help guide their policies in relation to insecticide-treated nets in pregnancy. The Cochrane Review<sup>14</sup> showed a clear effect in women of low parity on parasitemia and anemia. When data were extracted carefully on fetal loss, an interesting trend emerged, which in meta-analysis demonstrated statistical significance (  $p = .05$  ). This was a powerful message—that insecticide-treated nets reduced fetal loss—useful in communicating to pregnant women the true value of nets in terms of outcomes that have meaning to them.

**M I V I : F I D I O I I T I D I**

The world has been waiting a long time for a malaria vaccine: the cycle of promise and disappointment has been constant since the 1960s. By the mid-1990s, a good deal of early phase malaria vaccine research had been performed, much of it leading to dead ends for particular antigens. When starting to synthesize the evidence on this topic, trials with only immunologic (mainly antibody titers) endpoints were eliminated from consideration, and reviews were focused on trials that tested the efficacy of vaccines in preventing or mitigating disease (either in laboratory or natural challenge). Data on




Fig. 5. I c c - a a c . (From Ga b C, E a JP, K FO. I c c - a a a a a a c . C c a Da aba S R 2006;2; .)

adverse effects were extracted from immunologic trials for those vaccines that also had challenge endpoints in other trials.

Careful attention was paid to the stage of parasites used in a vaccine, the length of follow-up, the intensity of local transmission, and the effect of booster doses. A particular issue was how malaria cases were detected (active or passive), which can bias results, but were reported poorly in early trials. The authors believe that highlighting this in Cochrane Reviews has, resulted in standardized and improved collection methodology and reporting of outcomes in vaccine trials.

As trials of malaria vaccines have accumulated, what was originally a single Cochrane Review has been reorganized into three:

1. A systematic review that captures the history of SPf66 ( . 1 . 6)
2. One for pre-erythrocytic vaccines (intended to protect against or delay malaria infection)
3. One for blood-stage vaccines (intended to prevent invasion of red blood cells or diminish the severity of malaria)<sup>15-17</sup>

Together, they have helped to confirm a lack of effectiveness in Africa of SPf66, one early and controversial vaccine, and its limited effect outside Africa.<sup>17</sup> Another review

---




Fig. 6. SP 66 a a a acc . (From G a P, G ba H. Vacc a a a  
 (SP 66). C c a Da aba S R 2006;2; .)

**A** / / / **C** / / / : **I** / / / **P** / **D** **M** - /

Reviews of artemisinin derivatives<sup>21,22</sup> have evaluated 41 trials of various different artemisinin monotherapy and combination treatments, in various regimens and doses. In 1998, the systematic review then current was used by the WHO in considering next priorities in research in a meeting convened by the WHO in Ancey, France.<sup>23</sup>



Fig. 7. A a *Plasmodium falciparum* a a a. (From G a P, G ba H. Vacc a a a (SP 66). C c a Da aba S R 2006;2; )

Researchers recommended a more strategic approach to evaluating these compounds, giving them in combination with current first-line treatments within countries, to evaluate the effect on cure rate and other parameters.

A taskforce convened by the WHO's TDR encouraged a standard approach to trial design and facilitated formation of the International Artemisinin Study Group.<sup>24</sup> This group of researchers agreed to a standard protocol for meta-analysis using individual patient data across continents. This approach improves the quality of the meta-analysis. All trials were compiled in a single database; exclusions were dealt with in similar fashion, and the results synthesis was conducted as one analysis, stratified by drug and site. The trials and analysis took some 7 years to complete, and the meta-analysis was a substantive undertaking ( . . ). Representatives from each trial participated in a meeting to discuss the analysis and the results, and all agreed on the final manuscript, which gave the findings considerable weight. The effects showed that adding artemisinin derivatives for 3 days combined with the existing base drug used in the country resulted in substantially better cure rates than did monotherapy.<sup>24</sup> This systematic review, along with observational data on absolute cure rates and known pharmacologic effects of the drugs, helped the WHO make the recommendation that monotherapy no longer should be used, and wherever possible artemisinin-based combination therapy (ACT) be adopted for uncomplicated malaria.<sup>6,25</sup> That point now is considered settled science.

**H - -H C / A / / / -B C / / T / :**  
**A / G / R / A , D ,**  
**E / S /**

Once ACTs were established as the recommended first-line treatment for uncomplicated malaria, consideration of the best option needed evaluation, particularly as new combinations emerged, and resistance patterns varied around the world. A veritable explosion of trials obscured the overall picture. It is important, however, for the WHO to make timely decisions in this area.



an ACT that long has been used in Asia but has not been subject to extensive trials, is performing better than artemether–lumefantrine, the most tested ACT.<sup>26</sup>

***P* / *l* / *P* / *V* : *P* / *I* / *I* / *S* / *L***

---

For some years, the WHO has recommended a 14-day regimen of primaquine to prevent relapses of *Plasmodium vivax*, but in Sri Lanka and India, policy was for a 5-day regimen. A senior policy maker from Sri Lanka on study leave in Liverpool, United Kingdom, performed a Cochrane Review<sup>27</sup> of primaquine for preventing relapses of *P vivax* malaria with support from colleagues in India. As shown in **Fig. 10**, the included trials demonstrated lower relapse rates for *P vivax* with the 14-day regimen and no effect

This illustrates that there is often a gap between global policies set by the WHO and national guidelines. In this instance, a systematic review that involved policy staff from the relevant countries facilitated a rapid change in national guidelines in nesrom

collaborating on individual reviews. Within the collaboration, it is easy to avoid duplication and enable wide participation. This inclusiveness has encouraged groups in low- and middle-income countries to engage in the process. Cochrane Centers in Brazil, South Africa, India, China, and other locations help train and assist review authors working with the Cochrane Infectious Diseases Group and other Cochrane Review Groups reviewing trials in particular areas of medicine and health. A second reason it has been relatively easy to involve people from endemic regions is that the methods are clear, explicit, and made widely available through materials (including software developed by The Cochrane Collaboration) and training. The third reason has been extensive political and financial support from countries themselves (in supporting the centers listed previously) and other donors, including core support to the Cochrane Infectious Diseases Group from the UK Department for International Development. Finally, preparing a systematic review does not require vast amounts of resources, and for people in countries with constraints on research infrastructure, systematic reviews are a good way to do a valuable piece of research, assuming randomized controlled trials have been conducted on the question of interest. Although this is the case today for malaria, in some of the neglected diseases covered by the Cochrane Infectious Diseases Group, it is not. Systematic reviews can point to research needs, but a systematic review is only as good as the trials underpinning it.

Malaria is the best example from the Cochrane Infectious Diseases Group of systematic reviews contributing consistently to policy. Indeed, there are more trials in malaria than any other tropical infection; the global spotlight is on the condition,



3. Starr M, Chalmers I. The evolution of the Cochrane Library, 1988–2003. Available at: [www.update-software.com/history/clibhist.htm](http://www.update-software.com/history/clibhist.htm). Accessed November 20, 2008.
4. Garner P, Brabin B. A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. *Bull World Health Organ* 1994;72:89–99.
5. Chalmers I, Dickersin K, Chalmers TC. Getting to grips with Archie Cochrane's agenda. *BMJ* 1992;305:786–8.
6. World Health Organization. Roll Back Malaria Department: guidelines for the treatment of malaria. Geneva (Switzerland): World Health Organization; 2006.
7. GRADE working group. Available at: <http://www.gradeworkinggroup.org/>. Accessed November 20, 2008.
8. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
9. Garner P, Kramer MS, Chalmers I. Might efforts to increase birthweight in under-nourished women do more harm than good? *Lancet* 1992;340:1021–3.
10. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine–pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. *Lancet* 1999;353:632–6.
11. Garner P, Gülmezoglu AM. Drugs for preventing malaria in pregnant women. *Cochrane Database Syst Rev* 2006;4:CD000169.
12. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. *Cochrane Database Syst Rev* 2004;2:CD000363.
13. Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. *Am J Trop Med Hyg* 1996;55:50–6.
14. Gamble C, Ekwaru JP, ter Kuile FO. Insecticide-treated nets for preventing malaria in pregnancy. *Cochrane Database Syst Rev* 2006;2:CD003755.
15. Graves P, Gelband H. Vaccines for preventing malaria (blood-stage). *Cochrane Database Syst Rev* 2006;4:CD006199.
16. Graves P, Gelband H. Vaccines for preventing malaria (pre-erythrocytic). *Cochrane Database Syst Rev* 2006;4:CD006198.
17. Graves P, Gelband H. Vaccines for preventing malaria (SPf66). *Cochrane Database Syst Rev* 2006;2:CD005966.

24. Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. *Lancet* 2004;363:9–17.
25. Arrow KJ, Panosian CB, Gelband H, editors. Saving lives, buying time. Economics of malaria drugs in an age of resistance. Washington, DC: The National Academies Press; 2004.
26. Sinclair D, Zani B, Bukirwa H, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. *Cochrane Database Syst Rev*, in press.
27. Galappaththy GN, Omari AA, Tharyan P. Primaquine for preventing relapses in people with *Plasmodium vivax* malaria. *Cochrane Database Syst Rev* 2007;1: CD004389.
28. Higgins PT, Green S, editors. *Cochrane handbook for systematic reviews of interventions*. Chichester (UK): Wiley-Blackwell; 2008.
29. The Cochrane Collaboration. Available at: [www.cochrane.org](http://www.cochrane.org). Accessed November 5, 2008.